Latest Protease Stories
Avila Therapeuticsâ„¢, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.
A new technique that searches blood for the tiniest remnants of broken down proteins has revealed new information about how cells crank up cancer activators called proteases.
Nevirapine is widely used to help prevent mother-to-child transmission of the HIV virus. In cases where the infants are nonetheless infected with HIV virus at birth, the standard treatment is to use protease inhibitors (PI) to reduce the amount of virus in their bloodstream.
Scientists have obtained the closest look yet of how a gargantuan molecular machine breaks down unwanted proteins in cells, a critical housekeeping chore that helps prevent diseases such as cancer.
BRISBANE, Calif., July 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will release second quarter 2010 financial results on Tuesday, July 27, 2010 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m.
PALO ALTO, Calif., July 1, 2010 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D.
CAMBRIDGE, Mass., June 10 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc.
BRISBANE, Calif., April 22 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release first quarter 2010 financial results on Thursday, April 29, 2010 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m.
BRISBANE, Calif., March 26 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Scott Seiwert, Senior Vice President, Research and Technical Development of InterMune, will present at the Canaccord Adams Hepatitis C Conference in New York on April 1 at 11:15 a.m. EDT.
Suspecting that a particular protein in tuberculosis was likely to be vital to the bacteria's survival, Johns Hopkins scientists screened 175,000 small chemical compounds and identified a potent class of compounds that selectively slows down this protein's activity and, in a test tube, blocks TB growth, demonstrating that the protein is indeed a vulnerable target.
- A volcanic mudflow.